Abstract: A battery and an electronic device are disclosed. The battery includes: a first bare cell portion and a second bare cell portion. The first bare cell portion has a first surface and a side surface connected to the first surface, the first surface is configured to face towards a same direction as that of an opening of a battery compartment of an electronic device when the battery is installed in the battery compartment, and the side face is configured to face towards an inner side surface of the battery compartment of the electronic device when the battery is installed in the battery compartment. The second bare cell portion is located on a side that the first surface faces, and an orthographic projection of the second bare cell portion on the first surface overlaps the first surface.

Abstract: A battery charging and discharging management method. When the charging and discharging management method is implemented, an electronic device may set a lower-limit voltage of a battery to a voltage higher than a theoretical lower-limit voltage, and continuously increase the lower-limit voltage as a battery cycle passes, thereby reducing a charging/discharging volume change rate of a silicon anode as much as possible, and extending a battery life.

Abstract: This application provides a battery control circuit, an electronic device, and a charging control method. The battery control circuit is configured to control charging and discharging of a battery. The battery control circuit includes a processor and one or more charging links. The battery includes one or more bare cells. The charging link is electrically connected to the bare cell and the processor. The processor determines, based on a type of the bare cell, a charging policy to be performed by the charging link. In the foregoing design, several bare cells are integrated in one battery, so that different bare cells have independent charging and discharging functions.

Abstract: Disclosed are a salt form used as a CDC7 inhibitor and a crystal form thereof, and specifically disclosed is a compound represented by formula (II), a crystal form thereof, a preparation method thereof, and an application thereof in the preparation of a drug for preventing or treating tumors.

Abstract: A battery and an electronic device are disclosed. The battery includes: a first bare cell portion and a second bare cell portion. The first bare cell portion has a first surface and a side surface connected to the first surface, the first surface is configured to face towards a same direction as that of an opening of a battery compartment of an electronic device when the battery is installed in the battery compartment, and the side face is configured to face towards an inner side surface of the battery compartment of the electronic device when the battery is installed in the battery compartment. The second bare cell portion is located on a side that the first surface faces, and an orthographic projection of the second bare cell portion on the first surface overlaps the first surface.

Abstract: A battery and an electronic device are disclosed, which relate to the field of electronic device technologies, so that the battery has different characteristics to meet use requirements for the battery in different application scenarios. Specifically, the battery includes a first cell and a second cell, and the first cell is different from the second cell. The battery provided in embodiments of this application is configured to provide power for the electronic device.

Abstract: The battery provided in this application and having at least two ports is obtained by winding a first electrode and a second electrode that have a novel structure (for example, a plurality of tabs separately protrude from a first long side and a second long side of an electrode, and the tabs are disposed on a non-edge area). In addition, in the terminal device including the battery, the battery and another charging/discharging component may form at least two charging/discharging links, so that the terminal device can have a stronger fast charging capability, and heat dissipation pressure of each charging/discharging link can be relieved. Moreover, stress inside the battery is evenly distributed, so that interface deterioration of the electrode that is caused by stress unevenness can be alleviated. This effectively reduces a risk of shading and lithium plating generated in a cathode charging/discharging cycle, and improves performance of the battery.

Abstract: A tetracyclic compound as a Cdc7 inhibitor. Specifically disclosed is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.

Abstract: A new class of tetracyclic compounds acting as Cdc7 inhibitors; specifically disclosed are a compound represented by formula (I), isomers thereof, or pharmaceutically acceptable salts thereof.

Abstract: A battery includes an unpackaged cell and a packaging film, where an edge of the unpackaged cell includes at least one first open space. The first open space runs through a thickness direction of the unpackaged cell. No unpackaged cell exists in the first open space. The packaging film encloses an enclosed space that accommodates the unpackaged cell. The packaging film forms a first sealing part in the first open space. The first sealing part does not cover the unpackaged cell. The first sealing part encloses a second open space with a packaging film on a sidewall of the first open space. The first open space partly overlaps the second open space.

Abstract: A salt serving as an Akt inhibitor and a crystal thereof, specifically related to a salt of the compound of formula (I) and a crystal thereof.

Abstract: A salt serving as an Akt inhibitor and a crystal thereof, specifically related to a salt of the compound of formula (I) and a crystal thereof.

Abstract: A battery packaging material has both a high-temperature-resistant fireproof characteristic and a fire-retardant fireproof characteristic. The battery packaging material is successively disposed with a protective layer, a metal layer, and an encapsulating layer from outside to inside, where a first high-temperature-resistant layer is disposed between the metal layer and the protective layer; a second high-temperature-resistant layer is disposed between the metal layer and the encapsulating layer; and a fire-retardant layer is disposed above the protective layer, between the protective layer and the metal layer, between the metal layer and the encapsulating layer, or below the encapsulating layer.

Abstract: Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to linkers, containing amide surrogates with a regular or a novel lysosomal enzymatic cleavable dipeptidic unit, to connect cytotoxic drugs to antibodies. The present invention also relates to ADCs (antibody-drug conjugates) derived from these amide surrogate linkers for the treatment of cancers.

Abstract: The present invention relates to linkers, containing amide surrogates with a regular or a novel lysosomal enzymatic cleavable dipeptidic unit, to connect cytotoxic drugs to antibodies. The present invention also relates to ADCs (antibody-drug conjugates) derived from these amide surrogate linkers for the treatment of cancers.

Abstract: Provided are analgesic compounds, and salts thereof, of formula: (I) wherein A is: (A) Additionally, pharmaceutical formulations and methods of use employing the above compounds are provided.

Abstract: Provided are analgesic compounds, and salts thereof, of formula: (I) wherein A is: (A) Additionally, pharmaceutical formulations and methods of use employing the above compounds are provided.